158 related articles for article (PubMed ID: 24547931)
1. Immunosuppressive Treatment for Retinal Degeneration in Juvenile Neuronal Ceroid Lipofuscinosis (Juvenile Batten Disease).
Drack AV; Mullins RF; Pfeifer WL; Augustine EF; Stasheff SF; Hong SD
Ophthalmic Genet; 2015; 36(4):359-64. PubMed ID: 24547931
[TBL] [Abstract][Full Text] [Related]
2. Juvenile neuronal ceroid lipofuscinosis (Batten disease) CLN3 mutation (Chrom 16p11.2) with different phenotypes in a sibling pair and low intensity in vivo autofluorescence.
Mantel I; Brantley MA; Bellmann C; Robson AG; Holder GE; Taylor A; Anderson G; Moore AT
Klin Monbl Augenheilkd; 2004 May; 221(5):427-30. PubMed ID: 15162299
[TBL] [Abstract][Full Text] [Related]
3. Profound infantile neuroretinal dysfunction in a heterozygote for the CLN3 genetic defect.
de los Reyes E; Dyken PR; Phillips P; Brodsky M; Bates S; Glasier C; Mrak RE
J Child Neurol; 2004 Jan; 19(1):42-6. PubMed ID: 15032383
[TBL] [Abstract][Full Text] [Related]
4. Immunomodulation with minocycline rescues retinal degeneration in juvenile neuronal ceroid lipofuscinosis mice highly susceptible to light damage.
Dannhausen K; Möhle C; Langmann T
Dis Model Mech; 2018 Sep; 11(9):. PubMed ID: 30042155
[TBL] [Abstract][Full Text] [Related]
5. An Ophthalmic Rating Scale to Assess Ocular Involvement in Juvenile CLN3 Disease.
Dulz S; Atiskova Y; Wibbeler E; Wildner J; Wagenfeld L; Schwering C; Nickel M; Bartsch U; Spitzer MS; Schulz A
Am J Ophthalmol; 2020 Dec; 220():64-71. PubMed ID: 32707205
[TBL] [Abstract][Full Text] [Related]
6. [Juvenile neuronal ceroid lipofuscinosis (Batten-Mayou) disease. Ophthalmologic diagnosis and findings].
Seeliger M; Rüther K; Apfelstedt-Sylla E; Schlote W; Wohlrab M; Zrenner E
Ophthalmologe; 1997 Aug; 94(8):557-62. PubMed ID: 9376693
[TBL] [Abstract][Full Text] [Related]
7. Further Characterization of the Predominant Inner Retinal Degeneration of Aging Cln3
Volz C; Mirza M; Langmann T; Jägle H
Adv Exp Med Biol; 2018; 1074():403-411. PubMed ID: 29721970
[TBL] [Abstract][Full Text] [Related]
8. Loss of CLN3, the gene mutated in juvenile neuronal ceroid lipofuscinosis, leads to metabolic impairment and autophagy induction in retinal pigment epithelium.
Zhong Y; Mohan K; Liu J; Al-Attar A; Lin P; Flight RM; Sun Q; Warmoes MO; Deshpande RR; Liu H; Jung KS; Mitov MI; Lin N; Butterfield DA; Lu S; Liu J; Moseley HNB; Fan TWM; Kleinman ME; Wang QJ
Biochim Biophys Acta Mol Basis Dis; 2020 Oct; 1866(10):165883. PubMed ID: 32592935
[TBL] [Abstract][Full Text] [Related]
9. Ocular morphology and function in juvenile neuronal ceroid lipofuscinosis (CLN3) in the first decade of life.
Preising MN; Abura M; Jäger M; Wassill KH; Lorenz B
Ophthalmic Genet; 2017; 38(3):252-259. PubMed ID: 27486012
[TBL] [Abstract][Full Text] [Related]
10. Immunosuppression alters disease severity in juvenile Batten disease mice.
Seehafer SS; Ramirez-Montealegre D; Wong AM; Chan CH; Castaneda J; Horak M; Ahmadi SM; Lim MJ; Cooper JD; Pearce DA
J Neuroimmunol; 2011 Jan; 230(1-2):169-72. PubMed ID: 20937531
[TBL] [Abstract][Full Text] [Related]
11. Juvenile Batten Disease (CLN3): Detailed Ocular Phenotype, Novel Observations, Delayed Diagnosis, Masquerades, and Prospects for Therapy.
Wright GA; Georgiou M; Robson AG; Ali N; Kalhoro A; Holthaus SK; Pontikos N; Oluonye N; de Carvalho ER; Neveu MM; Weleber RG; Michaelides M
Ophthalmol Retina; 2020 Apr; 4(4):433-445. PubMed ID: 31926949
[TBL] [Abstract][Full Text] [Related]
12. Considerations in multi-gene panel testing in pediatric ophthalmology.
Turriff AE; Cukras CA; Brooks BP; Huryn LA
J AAPOS; 2019 Jun; 23(3):163-165.e1. PubMed ID: 30769084
[TBL] [Abstract][Full Text] [Related]
13. A novel c.1135_1138delCTGT mutation in CLN3 leads to juvenile neuronal ceroid lipofuscinosis.
Drack AV; Miller JN; Pearce DA
J Child Neurol; 2013 Sep; 28(9):1112-6. PubMed ID: 23877479
[TBL] [Abstract][Full Text] [Related]
14. OPTICAL COHERENCE TOMOGRAPHY IN JUVENILE NEURONAL CEROID LIPOFUSCINOSIS.
Hansen MS; Hove MN; Jensen H; Larsen M
Retin Cases Brief Rep; 2016; 10(2):137-9. PubMed ID: 26308342
[TBL] [Abstract][Full Text] [Related]
15. Protracted course of juvenile ceroid lipofuscinosis associated with a novel CLN3 mutation (p.Y199X).
Sarpong A; Schottmann G; Rüther K; Stoltenburg G; Kohlschütter A; Hübner C; Schuelke M
Clin Genet; 2009 Jul; 76(1):38-45. PubMed ID: 19489875
[TBL] [Abstract][Full Text] [Related]
16. Juvenile neuronal ceroid lipofuscinosis (JNCL) and the eye.
Bozorg S; Ramirez-Montealegre D; Chung M; Pearce DA
Surv Ophthalmol; 2009; 54(4):463-71. PubMed ID: 19539834
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of phosphodiesterase-4 inhibitors in juvenile Batten disease (CLN3).
Aldrich A; Bosch ME; Fallet R; Odvody J; Burkovetskaya M; Rama Rao KV; Cooper JD; Drack AV; Kielian T
Ann Neurol; 2016 Dec; 80(6):909-923. PubMed ID: 27804148
[TBL] [Abstract][Full Text] [Related]
18. Detailed Clinical Phenotype and Molecular Genetic Findings in CLN3-Associated Isolated Retinal Degeneration.
Ku CA; Hull S; Arno G; Vincent A; Carss K; Kayton R; Weeks D; Anderson GW; Geraets R; Parker C; Pearce DA; Michaelides M; MacLaren RE; Robson AG; Holder GE; Heon E; Raymond FL; Moore AT; Webster AR; Pennesi ME
JAMA Ophthalmol; 2017 Jul; 135(7):749-760. PubMed ID: 28542676
[TBL] [Abstract][Full Text] [Related]
19. Histopathologic and immunocytochemical analysis of the retina and ocular tissues in Batten disease.
Bensaoula T; Shibuya H; Katz ML; Smith JE; Johnson GS; John SK; Milam AH
Ophthalmology; 2000 Sep; 107(9):1746-53. PubMed ID: 10964839
[TBL] [Abstract][Full Text] [Related]
20. Phenotyping heterozygous carriers of juvenile neuronal ceroid lipofuscinosis with CLN3 mutations.
Bergholz R; Kohlschütter A; Schulz A; Hubert W; Rüther K
Graefes Arch Clin Exp Ophthalmol; 2015 Aug; 253(8):1245-50. PubMed ID: 25338278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
